Tenofovir

Results: 547



#Item
51Microsoft Word - GOCER-013.doc

Microsoft Word - GOCER-013.doc

Add to Reading List

Source URL: gilead.com

Language: English - Date: 2013-02-24 19:40:19
52This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

Add to Reading List

Source URL: gilead.com

Language: English - Date: 2013-02-25 18:48:52
53HIGHLIGHTS OF PRESCRIBING INFORMATION  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine

HIGHLIGHTS OF PRESCRIBING INFORMATION  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine

Add to Reading List

Source URL: www.gilead.com

Language: English - Date: 2013-10-28 13:55:09
54PATIENT INFORMATION VIREAD® (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be new information.

PATIENT INFORMATION VIREAD® (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be new information.

Add to Reading List

Source URL: www.gilead.com

Language: English - Date: 2015-05-29 13:25:40
55Microsoft Word - FPC QHP Policy Guide Febdoc

Microsoft Word - FPC QHP Policy Guide Febdoc

Add to Reading List

Source URL: fairpricingcoalition.org

Language: English - Date: 2014-02-05 17:34:29
56ISENTRESS ™(raltegravir), in Combination with tenofovir /lamivudine, Showed Durable and Potent Antiretroviral Activity in Treatment Naïve, HIV-1 Infected Patients, with Similar HIV RNA Reduction to Efavirenz in Combin

ISENTRESS ™(raltegravir), in Combination with tenofovir /lamivudine, Showed Durable and Potent Antiretroviral Activity in Treatment Naïve, HIV-1 Infected Patients, with Similar HIV RNA Reduction to Efavirenz in Combin

Add to Reading List

Source URL: www.msd-italia.it

Language: Italian - Date: 2013-02-13 08:58:47
    57Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia

    Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia

    Add to Reading List

    Source URL: shionogi616.tew-staging.com

    Language: English - Date: 2014-11-03 11:26:18
    58PATIENT INFORMATION VIREAD® (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be new information.

    PATIENT INFORMATION VIREAD® (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be new information.

    Add to Reading List

    Source URL: www.gilead.com

    Language: English - Date: 2015-05-29 07:25:40
    59FOR IMMEDIATE RELEASE Tokyo, March 2, 2015 JT and Torii sign agreement to market two new tenofovir alafenamide (TAF)-based anti-HIV drugs in Japan

    FOR IMMEDIATE RELEASE Tokyo, March 2, 2015 JT and Torii sign agreement to market two new tenofovir alafenamide (TAF)-based anti-HIV drugs in Japan

    Add to Reading List

    Source URL: www.jt.com

    Language: English - Date: 2015-03-01 21:32:08
    60IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT NO.: 5,935,946

    IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT NO.: 5,935,946

    Add to Reading List

    Source URL: www.pubpat.org

    Language: English - Date: 2007-12-21 07:53:28